Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06055881 | Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy(BOSS) | active not recruiting | N/A | 45 | Mayo ClinicOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06813053 | A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer | active not recruiting | N/A | 60 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02750826 | Breast Cancer WEight Loss Study (BWEL Study) | active not recruiting | Phase 3 | 3,177 | Alliance for Clinical Trials in OncologyOTHER | 4 | Sep 2, 2026 | clinicaltrials |
| NCT03270072 | The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients | active not recruiting | — | 100 | Massachusetts General HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03317405 | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | active not recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03946202 | KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer | active not recruiting | Phase 2 | 184 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT04540692 | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer(NEOSAMBA) | active not recruiting | Phase 3 | 446 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05548127 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | active not recruiting | Phase 1 / Phase 2 | 37 | PfizerINDUSTRY | 4 | Sep 2, 2026 | clinicaltrials |
| NCT02301767 | MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study | active not recruiting | — | 2,187 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03401385 | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | active not recruiting | Phase 1 | 890 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT06399276 | 4:3 Intermittent Fasting Intervention in Adults With Breast Cancer and Overweight or Obesity | active not recruiting | N/A | 36 | University of Colorado, DenverOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07798492 | Effects of Supervised Aerobic Exercise on Biomarkers, Physical Function, and Quality of Life in Breast Cancer Survivors | active not recruiting | N/A | 20 | Gazi UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT01901094 | Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy | active not recruiting | Phase 3 | 2,012 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 31, 2026 | clinicaltrials |
| NCT02954874 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | active not recruiting | Phase 3 | 1,195 | National Cancer Institute (NCI)NIH | 3 | Aug 31, 2026 | clinicaltrials |
| NCT02955394 | Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer | active not recruiting | Phase 2 | 61 | University of Colorado, DenverOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05460273 | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | active not recruiting | Phase 1 / Phase 2 | 119 | AstraZenecaINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT00070564 | S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer | active not recruiting | Phase 3 | 3,294 | SWOG Cancer Research NetworkNETWORK | 3 | Aug 28, 2026 | clinicaltrials |
| NCT00433511 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | active not recruiting | Phase 3 | 4,994 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | active not recruiting | Phase 3 | 5,018 | National Cancer Institute (NCI)NIH | 10 | Aug 28, 2026 | clinicaltrials |
| NCT02311933 | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | active not recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02849496 | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer | active not recruiting | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04427293 | Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 | 12 | University of Illinois at ChicagoOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06068985 | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade(CHERRY-PICK) | active not recruiting | Phase 2 | 63 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06428396 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | active not recruiting | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Aug 28, 2026 | clinicaltrials |
| NCT07462351 | System-integrated Point-of-Care Ultrasound in Breast Cancer Screening(SPRING) | active not recruiting | N/A | 4,800 | Region SkaneOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01824836 | A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | active not recruiting | N/A | 1,046 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 27, 2026 | clinicaltrials |
| NCT02685332 | Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA | active not recruiting | Phase 1 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06299124 | A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors | active not recruiting | Phase 1 | 40 | Regor Pharmaceuticals Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03995082 | Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey | active not recruiting | N/A | 925 | University of Colorado, DenverOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05306600 | Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System | active not recruiting | — | 882 | Hospital Moinhos de VentoOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05334732 | Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)(SIS) | active not recruiting | N/A | 225 | Virginia Commonwealth UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05767424 | Prospective Observational Study for Breast Microcalcifications' Classification With Artificial Intelligence Techniques | active not recruiting | — | 1,426 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05942105 | Different Localization Techniques for Non-palpable Breast Lesions Comparison: a Retrospective and Multicentric Clinical Study(Localization01) | active not recruiting | — | 1,064 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06577987 | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | active not recruiting | Phase 1 | 220 | Circle PharmaINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT01327781 | Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT07610148 | A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants | active not recruiting | Phase 1 | 21 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06590857 | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.(TRACY-1) | active not recruiting | Phase 1 / Phase 2 | 16 | RayzeBio, Inc.INDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04360941 | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer(PAveMenT) | active not recruiting | Phase 1 | 45 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT01450020 | Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors | active not recruiting | N/A | 145 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02728076 | MRI-Based Preoperative Accelerated Partial Breast Irradiation | active not recruiting | N/A | 39 | Medical College of WisconsinOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | active not recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06027268 | Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer(ToPCourT) | active not recruiting | Phase 2 | 36 | Wake Forest University Health SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 3, 2026source: clinicaltrials